Stege, C
87  results:
Search for persons X
?
1

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INT..:

Groen, K ; Stege, C ; Nasserinejad, K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171775/.  , 2023
 
?
2

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR..:

Smits, F ; Groen, K ; Stege, C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171806/.  , 2023
 
?
 
?
4

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN F..:

Groen, K ; Seefat, M ; Nasserinejad, K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430988/.  , 2022
 
?
5

Health-related quality of life in transplant ineligible new..:

Nielsen, LK ; Stege, C ; Lissenberg-Witte, B...
Nielsen , LK , Stege , C , Lissenberg-Witte , B , van der Holt , R , Mellqvist , UH , Salomo , M , Bos , G , Levin , MD , Visser - Wisselaar , H , Hansson , M , van der Velden , A , Deenik , W , Coenen , J , Hinge , M , Klein , S , Tanis , B , Szatkowski , D , Brouwer , R , Westerman , M , Leys , R , Sinnige , H , Haukas , E , van der Hem , K , Durian , M , Gimsing , P , van de Donk , N , Sonneveld , P , Waage , A , Abildgaard , N & Zweegman , S 2020 , ' Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study ' , Haematologica , vol. 105 , no. 6 , pp. 1650-1659 . https://doi.org/10.3324/haematol.2019.222299.  , 2020
 
?
7

Carfilzomib for relapsed and refractory multiple myeloma:

Groen, K ; van de Donk, N. W. C. J ; Stege, C..
info:eu-repo/semantics/altIdentifier/doi/10.2147/CMAR.S150653.  , 2019
 
?
8

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIAT..:

Seefat, M.R ; Stege, C.A.M ; Timmers, G.J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171826/.  , 2023
 
?
9

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INT..:

K. Groen ; C. Stege ; K. Nasserinejad...
http://journals.lww.com/10.1097/01.HS9.0000936180.78583.90.  , 2023
 
?
10

P18 SKIN EXPRESSION OF P16INK4A, A BIOMARKER FOR CELLULAR S..:

F. Smits ; K. Groen ; C. Stege...
http://journals.lww.com/10.1097/01.HS9.0000936200.69661.25.  , 2023
 
?
11

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN F..:

K. Groen ; M. Seefat ; K. Nasserinejad...
http://journals.lww.com/10.1097/01.HS9.0000846496.51905.dd.  , 2022
 
?
12

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED..:

K. Groen ; M. R. Seefat ; B. van der Holt...
http://journals.lww.com/10.1097/01.HS9.0000846492.51234.76.  , 2022
 
?
13

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIAT..:

M.R. Seefat ; C.A.M. Stege ; G.J. Timmers...
http://journals.lww.com/10.1097/01.HS9.0000936176.74423.76.  , 2023
 
?
 
?
15

Tolerability of BRAF and MEK Inhibitors for Metastasized Me..:

Salzmann, Martin ; Wald, Alexander ; Stege, Henner...
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/21832.  , 2023
 
1-15